NCT05063838

Perioperative Pharmacogenomic Testing

Perioperative Pharmacogenomic Testing (PPGx) : A Feasibility and Randomised Controlled Pilot Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Peter MacCallum Cancer Centre, Australia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single centre, prospective feasibility study and pilot randomised controlled trial of patients scheduled for elective intermediate or major non-cardiac surgery. The investigators plan to randomise up to 200 patients who meet the inclusion criteria to standard care or to personalised perioperative care based on pharmacogenomic testing for drugs commonly used in anaesthesia and postoperative pain management e.g., opioids - morphine, oxycodone and tramadol; anti-emetics - metoclopramide and ondansetron; and non-steroidal drugs - celecoxib and ibuprofen. The investigators hypothesise that pharmacogenomic testing is feasible prior to elective surgery and through 'personalised prescribing' for precision tailored perioperative care the investigators will improve patient's postoperative quality of recovery, including pain management.

Conditions

• Pharmacogenetics
• Anesthesia

Interventions

Type	Name	Description
OTHER	Pharmacogenomic optimisation of anaesthetic medications	Personalisation of anaesthetic plan based on pharmacogenomic results and international guidelines.

Timeline

• Start date: 2021-11-29
• Primary completion: 2023-11-01
• Completion: 2024-07-01
• First posted: 2021-10-01
• Last updated: 2023-05-23

Locations

1 site across 1 country: Australia